Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
about
Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphomaThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseLow incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention.Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysisComparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.Immunological basis for treatment of graft versus host disease after liver transplant.Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia WAnti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplantAntithymocyte globulin improves the survival of patients with myelodysplastic syndrome undergoing HLA-matched unrelated donor and haplo-identical donor transplants.Meta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.Group and within-group variable selection for competing risks data.Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly.Ocular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice.Emerging drugs for graft-versus-host disease.Novel approaches for preventing acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Classification systems for chronic graft-versus-host disease.Mechanistic approaches for the prevention and treatment of chronic GVHD.Novel strategies for improving hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation or intensive chemotherapy.Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older.Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.A review of late complications of allogeneic hematopoietic stem cell transplantations.Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.Effects of anti-human T lymphocyte immune globulins in patients: new or old.Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention.Dynamical system modeling to simulate donor T cell response to whole exome sequencing-derived recipient peptides: Understanding randomness in alloreactivity incidence following stem cell transplantation.Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease.Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie CBetter outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.
P2860
Q28072320-072F2D2F-D6AA-469A-9FE7-8E9F3F8492B3Q28076264-3AC1BE64-86B4-4E4F-A18F-13AC6C0CE74AQ30252205-1C379463-7D43-465F-BCC8-BCF50E93A62EQ33689153-DA09A5A9-9C20-4569-8C94-5C02DC1E581FQ33822026-83401EC0-6BE2-4969-BBE1-58E95C467BF1Q33868700-82E391EE-6E30-4E34-B548-66F642A0E034Q37035815-6029A325-1C2F-4DA2-A0DD-763168B25415Q37064425-A48E4ACE-4C5B-4466-8AA7-B202C24779F7Q37114440-BC9A06D4-2789-4B10-B756-C1DEBEF6FF7EQ37602434-144116F3-1F85-449B-9BEB-96FE419C6F43Q37618811-04F11F55-5319-4072-B9CE-6E1FF82D4459Q37618838-E7A81782-38D9-4EAD-BD3E-C8E17806CE5BQ37618840-093C811E-81A6-4DE8-BBA8-2D893B1E1C6EQ37681792-9D2A57B1-28D8-402F-96C2-28F1329CA2A6Q37706850-56F52DAA-9A68-4664-949D-B2D63B36E679Q38639634-8138C8DB-312F-444C-BE78-9DCD794F676EQ38728525-1BF49361-BF40-49D4-A7E9-CF917C8AA7A0Q38774962-EF858D6E-66F4-4C62-B1AE-64C6D0972C6EQ38786084-E80561A1-C1CE-4088-A521-8AF78FF7F2F3Q38816505-4F6CA109-DB58-47DA-A7DF-D7FB566A7E83Q38863489-8CF5D0D9-9818-4AD9-B1A8-2BBD2218A8B9Q39002161-4BCC6853-EB6B-485A-8A58-8C69865985ECQ39002166-804C475D-9942-4455-9572-6204B7D50C65Q39031745-8465533A-5691-4663-8440-B8648AD9F4ABQ39036486-032BF1C6-0F6C-4242-A5EB-02488CE52911Q39042251-E92E3F93-D45C-46FA-96D8-2B4370B7EE39Q39209778-7642E07E-2F3D-4861-A590-2EDFE434DFCAQ39972636-F9352F12-5CB3-43F5-A814-1BBC3C1F473DQ40094493-D8044A74-AC33-44AC-8BD7-4A534D226CEEQ40115697-687A9DF5-CAF0-48D4-86AA-AF07E0D10DF4Q40291317-518974BB-023D-440F-9200-6373FB1AA212Q40486613-85E18F27-2ABD-412E-819E-50E312FC4E0AQ40582651-96BB28A5-145C-4606-92B8-B0325050C62CQ40711913-FF1FE689-AE1D-488C-8165-C280AF141C0AQ42399882-F0494907-4468-49C5-802A-508BEAF9EEBBQ45074498-C84D4DE4-8460-44B4-BC98-3E5DA84838A3Q47161119-212DE93C-FAAC-46D9-8EAE-7418949EA63EQ48094910-2ABB7C30-CE6A-4FA8-91AA-0C07E3F31E07Q48144263-6F8CE0A1-E0D2-43AB-B676-3AA32F00ED57Q48251518-D8282256-148F-487B-99D2-697B351B2BA8
P2860
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
@en
type
label
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
@en
prefLabel
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.
@en
P2093
P50
P356
P1476
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
@en
P2093
Andreas Völp
Angelo Michele Carella
Antonio Risitano
Arnon Nagler
Carlos Solano
Carmine Selleri
Christelle Ferra
Christine Wolschke
Domenico Pastore
Domenico Russo
P356
10.1056/NEJMOA1506002
P407
P577
2016-01-01T00:00:00Z